Geode Capital Management
TRDA icon

Geode Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Geode Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.28M Buy
717,430
+50,083
+8% +$480K ﹤0.01% 2883
2026
Q1 		$8.42M Buy
667,347
+27,400
+4% +$314K ﹤0.01% 2471
2025
Q4 		$6.58M Sell
639,947
-5,172
-0.8% -$43.6K ﹤0.01% 2620
2025
Q3 		$3.74M Buy
645,119
+13,565
+2% +$79.4K ﹤0.01% 2929
2025
Q2 		$4.24M Buy
631,554
+42,479
+7% +$342K ﹤0.01% 2812
2025
Q1 		$5.33M Buy
589,075
+15,184
+3% +$189K ﹤0.01% 2623
2024
Q4 		$9.93M Sell
573,891
-2,560
-0.4% -$46.4K ﹤0.01% 2376
2024
Q3 		$9.21M Buy
576,451
+46,512
+9% +$733K ﹤0.01% 2433
2024
Q2 		$7.55M Buy
529,939
+54,581
+11% +$776K ﹤0.01% 2496
2024
Q1 		$6.74M Buy
475,358
+15,977
+3% +$226K ﹤0.01% 2543
2023
Q4 		$6.93M Buy
459,381
+20,800
+5% +$308K ﹤0.01% 2535
2023
Q3 		$6.93M Buy
438,581
+37,950
+9% +$598K ﹤0.01% 2471
2023
Q2 		$6.07M Buy
400,631
+216,841
+118% +$2.99M ﹤0.01% 2583
2023
Q1 		$2.66M Buy
183,790
+1,833
+1% +$24.5K ﹤0.01% 2913
2022
Q4 		$2.46M Buy
181,957
+14,839
+9% +$260K ﹤0.01% 2963
2022
Q3 		$2.63M Buy
167,118
+65,347
+64% +$830K ﹤0.01% 2989
2022
Q2 		$1.24M Sell
101,771
-75,962
-43% -$576K ﹤0.01% 3322
2022
Q1 		$1.67M Buy
177,733
+15,546
+10% +$167K ﹤0.01% 3350
2021
Q4 		$2.78M Buy
+162,187
New +$3.93M ﹤0.01% 3206

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Geode Capital Management's TRDA Position: Q2 2026 in Review

Geode Capital Management increased its Entrada Therapeutics (TRDA) stake by 7.5% in Q2 2026, buying an estimated $480K and bringing the position to 717,430 shares worth $5.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2883.

Geode Capital Management first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $9.93M in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Geode Capital Management held 717,430 shares of Entrada Therapeutics worth $5.28M as of Q2 2026.
  • Geode Capital Management bought 50,083 Entrada Therapeutics shares in Q2 2026, an estimated $480K.
  • Entrada Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2883 holding.
  • Geode Capital Management first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Geode Capital Management's Entrada Therapeutics position peaked at $9.93M in Q4 2024.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.